By: Dr. Elisabeth Oehrlein, Senior Director, Research and Programs In fall 2018, the NHC launched a new educational initiative on clinical outcome assessment (COAs). The webinar series is intended to […]
Patient Engagement
NHC VP of Policy and Gov. Affairs Joins Panel at HIMMS19
Eric Gascho, the NHC’s Vice President of Policy and Governmental Affairs, joined other health care leaders on a panel at HIMMS2019 to discuss private sector actions, policy recommendations, and national […]
NHC Releases Glossary of Patient Engagement Terms
This week, we published a glossary of terms related to patient engagement. The definitions of these terms, which includes Family Caregiver, Meaningful Engagement, and Patient-Focused Drug Development, stem largely from our patient engagement […]
How An Advocacy Group Elevates The Patient Voice In Research And Clinical Trials
Stevan W. Gibson, president and CEO of the Lupus Foundation of America wrote a guest column for the Clinical Leader on “How An Advocacy Group Elevates The Patient Voice In […]
It all starts with the “concept of interest” and “context of use”
Successful COAs: It all starts with the “concept of interest” and “context of use” This webinar featured T. Rosie Love, MPH, University of Maryland School of Pharmacy, Dept. Pharmaceutical Health […]
Glossary of Patient Engagement Terms
The definitions of these terms, which includes Family Caregiver, Meaningful Engagement, and Patient-Focused Drug Development, stem largely from our patient engagement work, including our ‘Patient-Focused Drug Development – Recommended Language […]
The NHC and NPC Partner to Publish Paper on Patient-Community Perspectives on Real-World Evidence
By: Jennifer Schleman, Senior Director, Marketing, Communications and Public Relations The National Health Council (NHC) and the National Pharmaceutical Council (NPC) co-authored Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, […]
Patient Engagement in Medical Device Clinical Trials Discussion Document
The National Health Council (NHC) is pleased to provide comments on the Food and Drug Administration (FDA)’s solicitation for feedback on patient engagement in medical device clinical trials, including the […]
Untangling the Terms: Endpoints, Items, Outcomes, PRO’s, PROMs, PRO-PMs
Untangling the Terms: Endpoints, Items, Outcomes, PRO’s, PROMs, PRO-PMs This webinar featured Ashley F. Slagle, MS, PhD, Principal, Aspen Consulting, LLC. Dr. Slagle provides strategic regulatory and scientific advice to […]
Patient-Focused Drug Development Guidance: Methods To Identify What Is Important to Patients and Select, Develop, or Modify Fit-for-Purpose Clinical Outcome Assessments
The National Health Council (NHC) is pleased to provide comments on the Food and Drug Administration’s (FDA) discussion documents related to Guidance 2: “Methods to Identify What is Important to […]